Table 1. Hydrogel Formulations Investigated in This Work along with Monomer Conversions (C) Measured for Each System and EWC in PBS.
| hydrogel formulationa | targeted DP | CTA/monomer/crosslinker/EY ratio | Cb (%)c | EWC (%)c |
|---|---|---|---|---|
| PEGDA | 50 | 1/50/0/0.00565 | 91 ± 1.9 | 85 ± 0.2 |
| PEGDA | 100 | 1/100/0/0.00565 | 95 ± 0.4 | 82 ± 0.2 |
| PEGMA-PEGDA (5 wt %) | 100 | 1/100/3.1/0.00565 | 100 ± 0.1 | 89 ± 1.1 |
| PEGMA-PEGDA (10 wt %) | 100 | 1/100/6.2/0.00565 | 100 ± 0.1 | 87 ± 0.5 |
| PDMAEMA-PEGDA (50 wt %) | 100 | 1/100/13.7/0.00565 | 100 ± 0.1 | 82 ± 0.1 |
| PDMA-NMBA (30 wt %) | 100 | 1/100/19.3/0.00565 | 93 ± 0.6 | 87 ± 1.2 |
| PDMA-NMBA (50 wt %) | 100 | 1/100/32.1/0.00565 | 95 ± 0.8 | 82 ± 0.3 |
a
The percentage in brackets refers to the amount of crosslinker used in relation to monomer. 0.5 mL of PBS were added to each formulation.
b
Monomer conversion was calculated via qNMR spectroscopy against potassium phthalate monobasic (PHP) as an internal standard.
c
Values arereported as average ± standard deviation (N = 3).